Xalkori

Xalkori

crizotinib

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Crizotinib
Indications/Uses
Advanced non-small cell lung cancer (NSCLC) whose tumors are anaphylastic lymphoma kinase (ALK) or ROS1 +ve.
Dosage/Direction for Use
250 mg bd until disease progression or intolerance.
Administration
May be taken with or without food: Swallow whole, do not crush/chew/open cap.
Contraindications
Special Precautions
Discontinue use in patients w/ new onset of severe visual loss; treatment-related pneumonitis. Avoid use in patients w/ congenital long QT syndrome. Patients w/ or w/o pre-existing cardiac disorders; symptomatic bradycardia; drug-induced hepatotoxicities; interstitial lung disease/pneumonitis. Regularly monitor heart rate & BP. Monitor on-treatment ECG & electrolytes; signs & symptoms of heart failure; liver function test including ALT, AST & total bilirubin every 2 wk during 1st 2 mth of treatment then once mthly. Avoid concomitant use w/ drugs causing bradycardia. Hepatic & severe renal impairment. May impair fertility. Women of childbearing potential should use effective contraception during & for 90 days after last dose. Not to be used during pregnancy & lactation. Ped patients. Elderly ≥65 yr.
Adverse Reactions
QT prolongation, bradycardia; vision disorder; vomiting, nausea, diarrhea, constipation, dyspepsia, dysphagia, abdominal pain, esophagitis; edema, pyrexia; upper resp infection; increased/decreased wt; pain in extremity, muscle spasm; dizziness, dysgeusia, headache, syncope, fatigue; decreased appetite, neuropathy; rash; renal cyst; dyspnea, pulmonary embolism; elevated transaminases, neutropenia, lymphopenia, hypokalemia, hypophosphatemia, increased blood creatine phosphokinase.
Drug Interactions
Increased plasma conc w/ strong CYP3A inhibitors eg, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin & voriconazole; grapefruit or grapefruit juice. Decreased plasma conc w/ strong CYP3A inducers eg, carbamazepine, phenobarb, phenytoin, rifabutin, rifampin & St. John's wort. Avoid concomitant use w/ CYP3A substrates, drugs prolonging QT interval, drugs causing bradycardia.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01ED01 - crizotinib ; Belongs to the class of anaplastic lymphoma kinase (ALK) inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Xalkori cap 200 mg
Packing/Price
60's
Form
Xalkori cap 250 mg
Packing/Price
60's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in